ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Knight Therapeutics Inc

Knight Therapeutics Inc (GUD)

5.73
0.04
(0.70%)
Closed April 27 4:12PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
5.73
Bid
5.70
Ask
5.88
Volume
41,264
5.68 Day's Range 5.84
4.35 52 Week Range 5.95
Market Cap
Previous Close
5.69
Open
5.81
Last Trade
30
@
5.73
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
74,090
Shares Outstanding
101,170,000
Dividend Yield
-
PE Ratio
-34.44
Earnings Per Share (EPS)
-0.17
Revenue
331.1M
Net Profit
-16.84M

About Knight Therapeutics Inc

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Montreal, Quebec, Can
Founded
1970
Knight Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the Toronto Stock Exchange with ticker GUD. The last closing price for Knight Therapeutics was $5.69. Over the last year, Knight Therapeutics shares have traded in a share price range of $ 4.35 to $ 5.95.

Knight Therapeutics currently has 101,170,000 shares outstanding. The market capitalization of Knight Therapeutics is $579.70 million. Knight Therapeutics has a price to earnings ratio (PE ratio) of -34.44.

GUD Latest News

Knight to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

MONTREAL, April 09, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia...

Knight Therapeutics Inc. ranks on The Globe and Mail’s fifth-annual Women Lead Here benchmark of executive gender diversity

MONTREAL, March 28, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”) is pleased to announce it will be recognized on The Globe and Mail’s 2024 Report on...

Knight Therapeutics Reports Fourth Quarter and Year-End 2023 Results

MONTREAL, March 21, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported...

Notice of Knight Therapeutics' Fourth Quarter and Year End 2023 Results Conference Call

MONTREAL, March 14, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and...

Knight Therapeutics Announces Launch of Minjuvi® in Brazil

MONTREAL, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of Minjuvi®...

Knight Therapeutics Inc. Celebrates its First Decade of Success

MONTREAL, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it is marking its...

Knight Therapeutics Announces Regulatory Submission of Fostamatinib in Brazil

MONTREAL, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian...

Knight Therapeutics Announces Launch of Bijuva® in Canada

MONTREAL, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a Pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of BIJUVA®...

Trading For This Specialty Pharma Company is up Following Second Quarter Results

This stock is almost a penny stock no longer, as shares moved close to the $5 threshold following the firm’s quarterly announcement. Leading pan-American (ex-US) specialty pharmaceutical...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.1-1.715265866215.835.885.56339865.74145532CS
40.427.909604519775.315.955.23581575.6651476CS
120.356.505576208185.385.955.21740905.47265309CS
261.2126.76991150444.525.954.42694145.36769516CS
520.9519.87447698744.785.954.35711955.03513607CS
1560.274.945054945055.466.24.281624055.26086414CS
260-1.55-21.29120879127.288.884.282341606.04400089CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BDRXBiodexa Pharmaceuticals PLC
$ 1.3254
(82.86%)
70.82M
IBRXImmunityBio Inc
$ 7.35
(43.84%)
40.28M
AGENAgenus Inc
$ 11.685
(40.78%)
3.37M
ULHUniversal Logistics Holdings Inc
$ 45.63
(38.74%)
484.22k
NIVFNewGenIvf Group Ltd
$ 1.77
(36.15%)
57.78M
MFImF International Ltd
$ 2.3153
(-77.82%)
21.23M
NWGLNature Wood Group Ltd
$ 5.05
(-70.03%)
2.48M
ICLKiClick Interactive Asia Group Ltd
$ 1.21
(-52.17%)
719.95k
NUWENewellis Inc
$ 0.1695
(-41.35%)
18.46M
SGBXSafe and Green Holdings Corporation
$ 0.1469
(-32.92%)
8.39M
PEGYPineapple Energy Inc
$ 0.065499
(26.20%)
325.57M
SQQQProShares UltraPro Short QQQ
$ 11.43
(-4.75%)
137.28M
INTCIntel Corporation
$ 31.88
(-9.20%)
119.84M
TSLATesla Inc
$ 168.29
(-1.11%)
109.84M
SOFISoFi Technologies Inc
$ 7.87
(3.69%)
88.63M

GUD Discussion

View Posts
sumotrader sumotrader 8 years ago
Loaded 1600 more shares today. GUD is about to take off.
👍️0
CommonCents4Dollars CommonCents4Dollars 9 years ago
This must be some sort of record,.. " the Company reported revenues of $109,608 and net income of $124,981,439."

http://www.gud-knight.com/en/knight-reports-fourth-quarter-and-year-ended-december-31-2014-results
👍️0
CommonCents4Dollars CommonCents4Dollars 9 years ago
Knight Therapeutics GUD.TO : Mackie Research starts with buy rating; target price of C$12

http://www.investorvillage.com/groups.asp?mb=6781&mn=83648&pt=msg&mid=14732670
👍️0
OneStepAhead OneStepAhead 9 years ago
On a tear
👍️0
CommonCents4Dollars CommonCents4Dollars 9 years ago
GOD is GUD. :)
👍️0
CommonCents4Dollars CommonCents4Dollars 9 years ago
KHTRF is the OTC Ticker for Americans
or
GUD on the TSX for Canadians


LONG on this one.
👍️0
CommonCents4Dollars CommonCents4Dollars 9 years ago
GUD is flying along nicely,.. Paladin II is in GUD hands, Goodman building another BEAST!
👍️0
OneStepAhead OneStepAhead 9 years ago
GUD Knight Therapeutics

Knight Therapeutics Inc. ("Knight" or the "Company") (TSX:GUD) today announced that it has entered into a bought deal agreement with a syndicate of underwriters led by GMP Securities L.P. and including Cormark Securities Inc., National Bank Financial Inc., Laurentian Bank Securities Inc., Bloom Burton & Co., Clarus Securities Inc., Mackie Research Capital Corporation and TD Securities Inc. (the "Underwriters"), pursuant to which the Underwriters have agreed to purchase 11,111,120 common shares of the Company (the "Common Shares") at a price of $6.75 per Common Share for gross proceeds to Knight of $75,000,060 (the "Offering"). In addition, the Underwriters will have the option, exercisable for a period of 30 days after the closing date, to acquire up to an aggregate of 1,666,668 additional Common Shares ($11,250,009) at the offering price to cover over-allotments, if any (the "Over-Allotment Option"). If the Over-Allotment Option is exercised in full, the total gross proceeds of the Offering shall be $86,250,069.

http://www.marketwired.com/press-release/knight-therapeutics-enters-into-agreement-75-million-bought-deal-common-shares-tsx-gud-1973898.htm
👍️0
OneStepAhead OneStepAhead 9 years ago
GUD Knight Therapeutics

After selling off his specialty pharmaceutical company Paladin Labs Inc. in a deal worth $3-billion, Montreal entrepreneur Jonathan Goodman is starting from scratch with a new drug distribution venture.

http://www.theglobeandmail.com/globe-investor/investment-ideas/a-fresh-stock-with-a-veteran-face/article17189152/
👍️0
Greedy G Greedy G 9 years ago
TNEN:

http://stockcharts.com/h-sc/ui?s=TNEN&p=D&b=5&g=0&id=p74917584188
👍️0

Your Recent History

Delayed Upgrade Clock